Allogeneic transplantation in 2026: What does the future hold? Developments and controversies
Tracks
-
| Sunday, April 19, 2026 |
| 4:20 PM - 5:50 PM |
| Hall 1B, Upper Level |
Details
Allogeneic transplantation provides a foundational curative option for patients with high-risk haematological malignancies but is undergoing unprecedented evolution in response to developments in graft versus host disease prevention, graft engineering and maintenance therapies. This session will address the major developments in the field all practising haematologists need to be aware of.
Speaker
Dr. Francesca Kinsella
Consultant Haemtologist, Director of BCCTT
Birmingham Centre of Cellular Therapy and Transplantation
Advances in Graft versus Host Disease
4:20 PM - 4:50 PM
Dr. Anjum Khan
Consultant
St James' Hospital, Leeds Teaching Hospitals NHS Trust
Allogeneic transplantation in 2026: From ‘Ultimate Therapy’ to ‘Immunotherapy Platform’
4:50 PM - 5:20 PM
Dr. Pramila Krishnamurthy
Consultant Haematologist
King's College Hospital, London
Preventing relapse of Acute Myeloid Leukaemia post-transplant – where are we in 2026
5:20 PM - 5:50 PM
Dr. Anjum Khan
Consultant
St James' Hospital, Leeds Teaching Hospitals NHS Trust
Session Chair
